Position statement concerning use of everolimus in the immunosuppressive therapy in patients after kidney transplantation

Abstract

Modified guidelines of immunosuppressive therapy with everolimus in renal transplant recipients based on results of recent clinical trials are presented. Everolimus after renal transplantation is used in de novo, in early or late conversion immunosuppressive regimens. Malignancy, viral infections are special indications for everolimus therapy. We do hope that presented position statement will help to identify patients who will benefit from everolimus therapy.